AOD-9604 Geriatric (65+) School and Activity Considerations

What Is AOD-9604 and Why Does Age Matter?

AOD-9604 is a 16-amino-acid fragment of human growth hormone, specifically the C-terminal region spanning positions 176 to 191. Early clinical work by Metabolic Pharmaceuticals in Australia tested it as an oral anti-obesity agent through the mid-2000s, and those trials reached Phase 3 before the program was discontinued for weight loss as a primary indication. The FDA granted AOD-9604 Generally Recognized as Safe (GRAS) status for use as a food ingredient in 2014, but that designation does not constitute approval as a therapeutic drug. The FDA GRAS notice GRN 000551 is publicly accessible on the FDA website.

Age reshapes nearly every variable relevant to peptide pharmacotherapy. Lean body mass declines roughly 1 to 2% per year after age 60 in the absence of resistance training, a process called sarcopenia, and this alters the tissue distribution and metabolic context in which a lipolytic peptide operates. Data from the Health ABC Study (N=3,075) showed that low appendicular lean mass was present in approximately 15% of adults aged 70 to 79. Renal clearance also falls with age, with GFR declining an estimated 0.75 mL/min/1.73 m² per year after 40, which changes how peptides are filtered and eliminated. This trajectory is documented in the MDRD study data available via PubMed.

The Lipolytic Mechanism in an Aging Metabolic Context

AOD-9604 binds to beta-3 adrenergic receptors and activates lipolysis through pathways similar to the intact growth hormone molecule, but without stimulating IGF-1 to the same degree. In younger adults with higher baseline adiposity, this mechanism produces measurable reductions in visceral fat. In older adults, visceral fat is already a primary cardiovascular risk contributor. Visceral adiposity and cardiovascular mortality in older adults were linked in a 2008 analysis published in the European Heart Journal. The question for geriatric prescribers is whether stimulating further lipolysis in someone already managing sarcopenic obesity carries a net benefit.

IGF-1, Growth Hormone Axis, and Aging

Growth hormone secretion declines with age. Average 24-hour GH secretion in healthy adults aged 60 to 80 is roughly 50% lower than in adults aged 20 to 30. This somatopause pattern is reviewed in the Journal of Clinical Endocrinology and Metabolism. AOD-9604 does not meaningfully raise IGF-1 in the clinical doses studied, which is one reason it was pursued as a potentially safer alternative to full-length GH peptides. Still, any agent touching the GH axis in a 70-year-old requires baseline IGF-1 measurement to establish a reference point.

Physical Activity Considerations for Older Adults Using AOD-9604

Physical activity is the single most evidence-supported intervention for preserving function, reducing fall risk, and managing body composition in adults over 65. The 2018 Physical Activity Guidelines for Americans (second edition) specify that older adults should accumulate at least 150 to 300 minutes of moderate-intensity aerobic activity weekly, plus two or more days of muscle-strengthening activity. The full guideline document is hosted by the HHS Office of Disease Prevention. AOD-9604, when used off-label by older adults, is almost always used alongside structured exercise. The peptide does not replace exercise. It may modestly augment lipolytic output during a caloric deficit, but that effect has not been demonstrated in geriatric populations specifically.

Resistance Training and Lean Mass Preservation

Resistance training is the primary tool for countering sarcopenia, and any fat-loss intervention used without concurrent resistance training risks accelerating lean mass loss. The LIFTMOR trial (N=101, postmenopausal women, mean age 65) demonstrated that high-intensity resistance and impact training for 8 months significantly improved bone mineral density and lean mass compared to low-intensity exercise. Older adults using AOD-9604 for body composition goals should undergo a resistance training program prescribed by a qualified exercise physiologist or physical therapist before, or simultaneously with, peptide initiation.

A practical three-component framework for older adults integrating AOD-9604 with exercise:

• Component 1 (Resistance, 2 days/week minimum): Compound movements targeting quadriceps, hip extensors, and upper back. Load should be sufficient to reach muscular fatigue within 8 to 12 repetitions.
• Component 2 (Aerobic, 150+ min/week): Walking, swimming, or cycling at moderate intensity. This preserves cardiovascular function and supports the caloric deficit that gives AOD-9604's lipolytic mechanism a substrate to work with.
• Component 3 (Balance and flexibility, 2 days/week): Tai chi or yoga-style balance work to reduce fall risk. Falls are the leading cause of injury death in adults 65 and older. CDC fall statistics are updated annually.

Timing AOD-9604 Around Exercise Sessions

Most investigational protocols administer AOD-9604 subcutaneously in the morning, approximately 30 minutes before the first meal or exercise session. This timing aligns with the peptide's proposed mechanism: lipolysis is most productive when insulin is low and catecholamine activity is rising, as occurs during early morning fasted or semi-fasted states. The role of insulin suppression on GH-related lipolysis is reviewed in a 2010 publication in Growth Hormone and IGF Research. Older adults who exercise in the late afternoon should discuss timing adjustment with their prescriber, as fasting windows may interact with diabetes medications or other glucose-modifying agents.

Fall Risk and Exercise Intensity Scaling

Adults aged 65 and older have a fall rate of approximately 30% per year, and about 10% of falls result in serious injury. This epidemiology is documented in a Cochrane review of fall prevention interventions (Sherrington et al., 2019, Cochrane Database of Systematic Reviews). Any exercise prescription in this age group must account for baseline balance, prior fall history, vision quality, and medication side effects including postural hypotension. AOD-9604 itself has not been reported to cause dizziness or postural hypotension in the published literature, but subcutaneous peptide injections in older adults with thin skin or anticoagulant therapy require careful injection-site technique.

Cognitive and Educational Program Participation (School Considerations)

The phrase "school considerations" in a geriatric context most commonly refers to adult education programs, continuing education, cognitive engagement activities, and memory-training courses that many older adults pursue as part of healthy aging. There is no published evidence connecting AOD-9604 to cognitive outcomes. However, this section addresses the practical intersection of peptide therapy management with structured learning programs.

Cognitive Engagement and Healthy Aging

Sustained cognitive engagement, including formal adult education, language learning, and skills training, is associated with reduced risk of cognitive decline. A 2019 meta-analysis in Neurology (N=29,549 across 11 studies) found that higher late-life cognitive activity was associated with a 46% reduction in dementia incidence. Older adults who remain active learners typically have better adherence to medical regimens, including self-administered peptide protocols that require consistent injection timing, refrigeration, and log-keeping.

Managing Injection Schedules Around Class or Activity Timetables

Structured programs such as community college courses, senior center fitness classes, or hospital-based wellness programs often run in fixed morning or midday windows. An older adult using AOD-9604 subcutaneously at 250 to 500 mcg daily needs to:

1. Store the reconstituted peptide at 2 to 8°C and use it within 28 days of reconstitution.
2. Administer the injection at a consistent time relative to meals and exercise.
3. Avoid injection immediately before activities that could raise core body temperature sharply, since heat may degrade residual peptide at the injection site.

These logistical demands are manageable but require planning. A prescribing clinician should review the patient's daily schedule before finalizing dosing instructions.

Polypharmacy Considerations in Older Learners

Adults aged 65 and older take an average of 4.5 prescription medications daily. Polypharmacy epidemiology in this cohort is reported by CDC National Health and Nutrition Examination Survey data. AOD-9604 is not a regulated pharmaceutical in the United States, so it will not appear in standard drug interaction databases. Clinicians must manually assess for interactions with insulin secretagogues, metformin, thyroid medications, and anticoagulants when recommending this peptide. No peer-reviewed drug interaction studies for AOD-9604 in polypharmacy geriatric patients have been published.

Dosing and Safety Monitoring in Adults Aged 65 and Older

No published randomized trial has tested AOD-9604 specifically in adults 65 and older. The Phase 2b and Phase 3 trials conducted by Metabolic Pharmaceuticals enrolled predominantly middle-aged adults (mean age approximately 44 to 52 years in available summaries). Extrapolating from those populations to geriatric patients requires caution.

Suggested Monitoring Parameters

A conservative monitoring framework for off-label AOD-9604 use in older adults should include the following at baseline and every 12 weeks:

• Fasting plasma glucose and HbA1c (to detect any glucose metabolism changes)
• IGF-1 (to document GH-axis baseline and detect unexpected elevation)
• Comprehensive metabolic panel including creatinine and eGFR (given age-related renal decline)
• DEXA scan at baseline and at 6 months (to track fat mass and lean mass separately)
• Blood pressure and resting heart rate (cardiovascular safety monitoring)

DEXA-based body composition assessment methodology and reference data for older adults are available through the International Society for Clinical Densitometry guidelines.

Dose Adjustments for Renal Impairment

The pharmacokinetic profile of AOD-9604 in patients with CKD stage 3 or higher (eGFR <60 mL/min/1.73 m²) has not been studied in published literature. Given that small peptides are predominantly cleared renally, a conservative starting approach would be to begin at the lower end of the studied range (250 mcg/day) and assess tolerability over 4 to 6 weeks before any upward adjustment. This is not a published guideline recommendation; it reflects the general principle of "start low, go slow" that the American Geriatrics Society applies to new pharmacotherapy in older adults. The AGS Beers Criteria, updated in 2023, outlines pharmacokinetic aging considerations broadly relevant to novel agents.

Hypoglycemia Risk

In Phase 2 trials, AOD-9604 did not significantly alter fasting insulin or glucose at doses up to 1 mg/day in non-diabetic adults. This was reported in the original Metabolic Pharmaceuticals Phase 2 data summarized in a 2004 publication in Obesity Research. Older adults with type 2 diabetes managed with sulfonylureas or insulin represent a higher-risk subgroup. The combination of a lipolysis-stimulating peptide with insulin sensitizers could theoretically lower postprandial glucose further, and clinicians should check fasting glucose at 4 and 8 weeks after initiation in any diabetic patient over 65.

Regulatory and Compounding Field

AOD-9604 is not approved by the FDA as a drug. It is available from compounding pharmacies as a research compound and is typically dispensed as a lyophilized powder for reconstitution with bacteriostatic water. The FDA's 2023 and 2024 actions on peptide compounding have shifted which compounds may be legally prepared by 503A and 503B pharmacies. The FDA's current position on compounded peptides is detailed in its guidance documents for compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Older adults and their caregivers should verify that any AOD-9604 product comes from an FDA-registered compounding pharmacy with a valid Certificate of Analysis confirming peptide identity and purity. Using unverified sources increases the risk of receiving a product with incorrect peptide concentration, bacterial contamination, or no active ingredient at all.

The Endocrine Society's clinical practice guidelines on growth hormone use state: "GH treatment should not be recommended for healthy elderly patients as an anti-aging therapy." This language appears in the 2019 Endocrine Society GH guideline published in JCEM. While AOD-9604 is not full-length GH, this conservative posture from the Endocrine Society reflects the general principle that GH-axis agents require rigorous justification in older adults.

Special Populations Within the Geriatric Cohort

Adults Aged 75 and Older

The so-called "oldest old" (age 75 and above) face compounding physiological changes that make AOD-9604 use even less studied. Subcutaneous fat distribution shifts significantly with advanced age, altering both the mechanics and absorption kinetics of subcutaneous injections. Age-related changes in subcutaneous adipose tissue distribution are reviewed in a 2015 paper in Ageing Research Reviews. Prescribers should assess injection-site skin integrity and consider rotating among multiple sites (abdomen, anterior thigh, lateral arm) to minimize tissue trauma.

Postmenopausal Women

Postmenopausal women experience accelerated visceral fat accumulation driven by estrogen withdrawal. The SWAN study (Study of Women's Health Across the Nation, N=1,054) documented a 49% increase in intra-abdominal fat area across the menopausal transition. AOD-9604's lipolytic mechanism has theoretical relevance for this phenotype. Whether it adds meaningful benefit beyond structured exercise and dietary intervention in this group remains unknown, as no trial has tested this combination directly.

Older Men With Andropause

Testosterone declines roughly 1 to 2% per year after age 30 in men, contributing to visceral fat gain that accelerates in the sixth and seventh decades. This trajectory is documented in the Massachusetts Male Aging Study. Men on testosterone replacement therapy (TRT) who also consider AOD-9604 should know that both agents affect body composition through different mechanisms. TRT increases lean mass primarily; AOD-9604 targets lipolysis. The combination has not been studied in older men in any published trial.

Practical Checklist for Geriatric Patients and Their Clinicians

Before initiating AOD-9604 in any patient aged 65 or older, the following steps should be completed:

1. Establish baseline body composition with DEXA, including appendicular lean mass index to screen for sarcopenia.
2. Measure fasting glucose, HbA1c, IGF-1, comprehensive metabolic panel, and complete blood count.
3. Calculate eGFR and review all current medications for theoretical interactions.
4. Confirm the compounding pharmacy's regulatory registration and request a Certificate of Analysis.
5. Design a concurrent resistance training program with a qualified professional before the first peptide dose.
6. Schedule a 4-week follow-up visit to assess injection-site tolerance, glucose response, and subjective well-being.
7. Reassess body composition at 3 and 6 months. If lean mass has declined by more than 2% without corresponding fat loss, reconsider continuation.